Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW906 in Essential Hypertension
NCT07835971Phase 2Active, not recruiting
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
A Phase 2 trial of GW906 in essential hypertension, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Started Dec 2025; status: active, not recruiting.
02
Drugs
GW906
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT07835971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07835971.